Rock Creek Group, LP Verve Therapeutics, Inc. Transaction History
Rock Creek Group, LP
- $1.05 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding VERV
# of Institutions
170Shares Held
78.3MCall Options Held
125KPut Options Held
185K-
Alphabet Inc. Mountain View, CA12.3MShares$64.8 Million7.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.33MShares$33.2 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl6.04MShares$31.7 Million0.57% of portfolio
-
Black Rock Inc. New York, NY5.37MShares$28.2 Million0.0% of portfolio
-
State Street Corp Boston, MA5.1MShares$26.8 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $315M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...